Event Type
Disclosure
Voluntary
Variant
8-K
. Regulation FD Disclosure. Furnished herewith as Exhibits 99.1, 99.2 and 99.3 are, respectively, the February 2026 Corporate Presentation, a Year-End Interim C
. Other Events. A Phase I/II Open Label Study of Durvalumab (Imfinzi) and Rintatolimod (Ampligen) in pancreatic cancer patients with stable disease Post-FOLFIRI
. Financial Statements and Exhibits. (d) Exhibits The following exhibits are filed herewith: Exhibit Number Description 99.1 AIM February 2026 Corporate Present